--- title: "Esperion Therap | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 168.45 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/278543899.md" datetime: "2026-03-10T11:19:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278543899.md) - [en](https://longbridge.com/en/news/278543899.md) - [zh-HK](https://longbridge.com/zh-HK/news/278543899.md) --- # Esperion Therap | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 168.45 M Revenue: As of FY2025 Q4, the actual value is USD 168.45 M, beating the estimate of USD 166.12 M. EPS: As of FY2025 Q4, the actual value is USD 0.22. EBIT: As of FY2025 Q4, the actual value is USD 107.87 M. #### Total Revenue Esperion Therapeutics, Inc. reported total revenue of $168.4 million for the three months ended December 31, 2025, an increase of 144% from $69.1 million in the comparable period of 2024. For the full year ended December 31, 2025, total revenue was $403.1 million, a 21% increase from $332.3 million in 2024. #### U.S. Net Product Revenue U.S. net product revenue for the three months ended December 31, 2025, was $43.7 million, an increase of approximately 38% from $31.6 million in the comparable period of 2024. For the full year 2025, U.S. net product revenue was $159.6 million, an increase of approximately 38% from $115.7 million in 2024. #### Collaboration Revenue Collaboration revenue was $124.7 million for the three months ended December 31, 2025, up 232% from $37.6 million in the comparable period of 2024. For the full year 2025, collaboration revenue was $243.6 million, an increase of 12% from $216.6 million in 2024. This increase was driven by a one-time $90 million payment from Otsuka related to regulatory approval and favorable NHI Price listing, as well as increases in royalty sales and product sales to collaboration partners. #### Royalty Revenue Royalty revenue was $14.6 million in Q4 2025, representing a 51% increase from Q4 2024 and an 11% sequential decrease. #### Cost of Goods Sold Cost of goods sold was $27.9 million for the three months ended December 31, 2025, compared to $25.6 million in the prior year period. For the full year 2025, cost of goods sold was $129.2 million, up from $68.6 million in 2024. #### Research and Development (R&D) Expenses Research and development expenses were $13.9 million for the three months ended December 31, 2025, a 26% increase from $11.0 million in the comparable period of 2024. For the full year 2025, R&D expenses were $47.9 million, a 4% increase from $46.2 million in 2024, primarily due to increased costs for ongoing clinical studies related to the pediatric program. #### Selling, General and Administrative (SG&A) Expenses Selling, general and administrative expenses were $41.4 million for the three months ended December 31, 2025, an increase of 12% from $36.9 million in the comparable period of 2024. For the full year 2025, SG&A expenses were $165.8 million, a 2% increase from $163.1 million in 2024, mainly related to increased legal costs associated with ANDA litigation. #### Income (Loss) from Operations Income from operations was $85.2 million for the three months ended December 31, 2025, compared to a loss of -$4.4 million in the comparable period of 2024. For the full year 2025, income from operations was $60.3 million, up from $54.4 million in 2024. #### Interest Expense Interest expense was -$22.6 million for the three months ended December 31, 2025, compared to -$16.4 million in the prior year period. For the full year 2025, interest expense was -$84.6 million, compared to -$59.3 million in 2024. #### Loss on Extinguishment of Debt There was no loss on extinguishment of debt for the three months or full year ended December 31, 2025, compared to -$1.7 million for Q4 2024 and -$54.9 million for full year 2024. #### Other Income, Net Other income, net, was $1.1 million for the three months ended December 31, 2025, compared to $1.2 million in the prior year period. For the full year 2025, other income, net, was $3.5 million, compared to $8.0 million in 2024. #### Net Income (Loss) Esperion Therapeutics, Inc. reported net income of $61.8 million for the three months ended December 31, 2025, compared to a net loss of -$21.3 million in the comparable period of 2024. For the full year 2025, the company had a net loss of -$22.7 million, compared to a net loss of -$51.7 million in 2024. #### Cash and Cash Equivalents As of December 31, 2025, cash and cash equivalents totaled $167.9 million, compared to $144.8 million as of December 31, 2024. #### Working Capital Working capital was $161.8 million as of December 31, 2025, up from $91.8 million as of December 31, 2024. #### Total Assets Total assets were $465.9 million as of December 31, 2025, compared to $343.8 million as of December 31, 2024. #### Royalty Sale Liability Royalty sale liability was $295.8 million as of December 31, 2025, compared to $293.6 million as of December 31, 2024. #### Convertible Notes, Net of Issuance Costs Convertible notes, net of issuance costs, were $97.3 million as of December 31, 2025, down from $151.3 million as of December 31, 2024. #### Long-Term Debt Long-term debt was $152.2 million as of December 31, 2025, compared to $141.0 million as of December 31, 2024. #### Total Stockholders’ Deficit Total stockholders’ deficit was -$302.0 million as of December 31, 2025, compared to -$388.7 million as of December 31, 2024. #### Operational Metrics Q4 retail prescription equivalents grew 34% year-over-year and 11.3% quarter-over-quarter. The number of unique healthcare providers prescribing NEXLETOL and NEXLIZET increased by 24% in 2025, from 36,311 to 44,991. Daiichi Sankyo Europe has treated over 700,000 patients with bempedoic acid therapies to date across 30 countries in the European Union. The market opportunity for Enbumyst in the U.S. is estimated to exceed $4 billion. #### Outlook / Guidance Esperion Therapeutics, Inc. expects full-year 2026 operating expenses to be in the range of $225 million to $255 million. This range includes approximately $15 million in non-cash expenses related to stock compensation. ### Related Stocks - [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md) ## Related News & Research - [Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference](https://longbridge.com/en/news/282600951.md) - [SemiLEDs Reports Second Quarter Fiscal Year 2026 Financial Results | LEDS Stock News](https://longbridge.com/en/news/282650581.md) - [Hyatt Studios Jacksonville / St. Johns Town Center Now Open | H Stock News](https://longbridge.com/en/news/283023403.md) - [Pineapple Financial Reports Fiscal Q2 2026 Financial Results and Provides Digital Asset Treasury Update | PAPL Stock News](https://longbridge.com/en/news/282587469.md) - [Key facts: Bloom Energy supply 2.8 GW; files 8-K on unregistered sales](https://longbridge.com/en/news/282739037.md)